Avanos Medical ( (AVNS) ) has provided an announcement.
On April 18, 2025, Avanos Medical announced the departure of Michael C. Greiner, who had served as Interim CEO and previously as CFO and Chief Transformation Officer. Greiner’s exit follows the appointment of Dave Pacitti as CEO on April 14, 2025. Greiner will receive a severance package, including a $2.1 million payment, prorated bonus, and consulting fees. Additionally, Jason M. Pickett has been appointed as Interim CFO and Treasurer, effective April 14, 2025, following Warren J. Machan’s transition to a consulting role. These leadership changes indicate a strategic shift within Avanos Medical, potentially impacting its operational focus and stakeholder relations.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score reflects a mix of moderate financial performance and weak technical indicators. The company’s net losses and negative valuation metrics are significant concerns. However, the recent appointment of a new CEO and strategic initiatives may offer potential for future growth. Current challenges in operational efficiency and a negative market sentiment keep the score on the lower side.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical, Inc. operates in the medical device industry, focusing on providing innovative healthcare solutions. The company offers a range of products and services aimed at improving patient outcomes and enhancing the quality of care in various medical settings.
YTD Price Performance: -21.48%
Average Trading Volume: 506,554
Technical Sentiment Signal: Buy
Current Market Cap: $554.8M
For an in-depth examination of AVNS stock, go to TipRanks’ Stock Analysis page.